Medicare Enrolled

Dr. Scott Witherspoon, MD

Ophthalmology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
3414 OAK GROVE AVE, Dallas, TX 75204
2145211153
In practice since 2007 (19 years)
NPI: 1639203169 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Witherspoon from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Witherspoon? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Witherspoon

Dr. Scott Witherspoon is an ophthalmology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Witherspoon performed 23,412 Medicare services across 3,949 unique beneficiaries.

Between the years covered by Open Payments, Dr. Witherspoon received a total of $305 from 6 pharmaceutical and/or device companies across 10 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Witherspoon is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 4% volume in TX$ $305 industry payments

Medicare Practice Summary

Medicare Utilization ↗
23,412
Medicare services
Top 4% in TX for ophthalmology
3,949
Unique beneficiaries
$107
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,232 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Injection, ranibizumab, 0.1 mg8,209$178$429
Eye injection (Vabysmo/faricimab)3,900$29$40
Eye exam, established patient, focused3,474$64$139
Retinal imaging (OCT scan)3,331$29$90
Eye injection for retinal disease2,505$97$602
Compounded drug, not otherwise classified950$75$193
Aflibercept eye injection (Eylea)262$690$980
Comprehensive eye exam, new patient240$104$253
Comprehensive eye exam, established patient156$85$196
Retinal photography (fundus photo)136$26$152
Exam of retinal blood vessels using a special camera after injection of a dye97$107$267
Injection, bevacizumab, 10 mg42$35$165
Destruction of eye fluid (vitreous) between lens and retina using a laser26$766$2,147
Extended exam of the back part of the eye with retinal drawing17$17$52
2d ultrasound scan of eye tissue and structures16$39$234
Removal of membrane of retina with removal of internal limiting membrane of retina14$856$2,484
Destruction of growth of retina using a laser13$399$1,201
Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser12$756$2,472
Complex repair of detached retina and drainage of eye fluid between lens and retina12$1,061$2,867
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$305
Total received (2018-2024)
Avg $51/year across 6 years
Bottom 18% in TX for ophthalmology
6
Companies
10
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$305 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$158
2023
$13
2022
$16
2021
$20
2019
$62
2018
$37

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
JAZZ PHARMACEUTICALS INC.
$129
EyePoint Pharmaceuticals US, Inc.
$48
Novartis Pharmaceuticals Corporation
$44
Regeneron Healthcare Solutions, Inc.
$36
Genentech USA, Inc.
$28
Mallinckrodt LLC
$19
Top 3 companies account for 72.6% of total payments
Associated products mentioned in payments ›
ACTHAR · DEFITELIO · DEXYCU · DUREZOL · EYLEA · EYLEA AFLIBERCEPT INJECTION · Vabysmo · YUTIQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $1 per 100 Medicare services performed
Looking for a ophthalmology in Dallas?
Compare ophthalmologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologys nearby

Geographic Context

Ophthalmologys within 10 mi
287
Per 100K population
11.0
County median income
$74,149
Nearest hospital
BAYLOR SCOTT AND WHITE MEDICAL CENTER UPTOWN
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Witherspoon is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Witherspoon experienced with injection, ranibizumab, 0.1 mg?
Based on Medicare claims data, Dr. Witherspoon performed 8,209 injection, ranibizumab, 0.1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Witherspoon receive payments from pharmaceutical companies?
Yes. Dr. Witherspoon received a total of $305 from 6 companies across 10 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Witherspoon's costs compare to other ophthalmologys in Dallas?
Dr. Witherspoon's average Medicare payment per service is $107. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Witherspoon) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →